Can remote monitoring help teens with diabetes? new study says yes

NCT ID NCT04540536

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether real-time remote blood sugar monitoring and secure texting could help teens (ages 13-18) with poorly controlled type 1 diabetes improve their blood sugar levels. Twenty teens wore a continuous glucose monitor that shared their readings with the study team, who provided support via text messages for three months. The main goal was to see if this approach lowered their HbA1c, a key measure of long-term blood sugar control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Nov 2021

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

13 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Age between 13-18 * Diagnosis of type 1 diabetes for at least six months. * Both sexes and all ethnicities included. * Subject and at least one parent able to communicate in English. * Poorly controlled T1D as evidenced by a \>30% annual risk of developing DKA in the following year OR Hemoglobin A1c ≥ 12% * Treated with subcutaneous insulin, either with a basal/bolus insulin regimen or a continuous subcutaneous insulin infusion (CSII) device. * Willing to wear CGM and utilize the share function to clinician and guardian, with measuring blood glucose checks as required by the CGM. * Owning a smartphone compatible with Dexcom G6 software to allow the use of share/follow features with internet access capabilities * Willing to participate in secure text messaging with study personnel. * Female participants must have a negative pregnancy test. Exclusion criteria * Type 2 diabetes, secondary diabetes or CF related diabetes. * Other severe chronic disease (e.g., cancer) which in the judgment of the investigator is likely to significantly affect glycemic control. * Patients cannot be taking systemic corticosteroids at enrollment because of adverse effects on glycemic control, but we will not disqualify subjects who require such therapy during the study. Inhaled or topical corticosteroids are permissible. * Patients with uncontrolled hypothyroidism (TSH \>20) or uncontrolled hyperthyroidism will be excluded from the study. Patients with out of range values may be retested after medication dose adjustment. * Developmental delay or behavioral disorder in the patient of sufficient severity, in the judgment of the investigator, to interfere with study activities. Severe uncontrolled depression defined as PHQ-9A \>15 at time of enrollment is an exclusion criterion. * Medical or psychiatric disorder in a parent of sufficient severity, in the judgment of the investigator, to interfere with study activities. * Pregnancy, planned pregnancy or breast feeding * CGM adhesive allergy * Skin condition that makes CGM placement contraindicated. * Sickle cell disease or hemoglobinopathy * Red blood cell transfusion within 3 months prior to study enrollment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus, type 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Childrens Medical Center

    Dallas, Texas, 75390, United States

  • UT Southwestern Medical Center

    Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.